MedTrace Logo

Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma

NCT02393820 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2019-10-29

No results posted yet for this study

Summary

Open-label, multicenter, single arm phase II study, set up in collaboration with the "Réseau d'Expertise Français sur les Cancers ORL Rares" (REFCOR), evaluating the activity and safety of single agent pazopanib in recurrent or metastatic tumors in salivary gland including adenoid cystic carcinoma (ACC) and to exploring the activity and safety of pazopanib in non-adenoid cystic carcinoma (non-ACC).

Conditions

  • Salivary Gland Carcinoma

Interventions

DRUG

pazopanib

treatment will be given until progression or unacceptable toxicity .

Sponsors & Collaborators

  • UNICANCER

    lead OTHER

Principal Investigators

  • Joel Mr Guigay, Pr · Centre Lacassagne Nice

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-26
Primary Completion
2015-12-31
Completion
2019-10-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02393820 on ClinicalTrials.gov